#mrna Community Insights & Market Sentiment

$MRNA plunged yesterday from a high of 249.9 to 181.1, wiping out nearly 30% in a single day. The intraday low came within a whisker of the daily Bollinger lower band at 181.8. The trigger was an early leak of data from the cancer vaccine developed in partnership with Merck; when the full data came out later, it didn’t look bad, but the stock still got hammered. The positioning in the contracts made things even stranger: before the sell-off, large traders’ longs accounted for only a little over 40% of their positions—in other words, big players were short. After the plunge, that same metric climbed steadily to 65.3%, while the share of accounts net long across the market rose from 42% to 55%. Once cheap shares became available, more people stepped in to catch the falling knife than there had been before the sell-off.

After the U.S. market opened today, the spot price recovered to around 200, up nearly 10% from the low of 183. Yahoo’s intraday high just touched 201. But Binance open interest has already fallen from its midday peak of 25,000 contracts to 20,800, down about 17%; the large-trader long-position ratio has also retreated from 65% to 54.7%. Price is rising while open interest is falling. The mechanics are straightforward: traders who bought the dip yesterday are using this post-open rebound to reduce their positions; new longs aren’t taking over. Funding rates have stayed at zero for several periods, suggesting neither side is fully levered up. This move is more about positions being redistributed than a funding-rate squeeze.

The daily EMA12 is still at 217, and the Bollinger midline is at 215—nearly 10% above the current price. The daily RSI14 has recovered to 46.7, while the KDJ J value is just 22: oversold conditions have only just eased, and there’s no reversal signal yet. The 4-hour RSI is still at 32.8, and the bearish structure remains intact. The daily Bollinger lower band at 181.8 and today’s low of 183 are at essentially the same level. If that level breaks, the price could fall by another daily ATR, roughly 20 points.

I’m treating the area around 200 as a window to trim positions after the sell-off, not as a trend reversal. The rebound could first reach the 208–217 area. A return of open interest to around 25,000 contracts, along with large traders’ long-position ratio moving back above 60%, would be a sign that buyers are stepping in with real money. For me to change my view, the daily close would need to reclaim the EMA12 at 217, and open interest would need to hold steady. I don’t have a position in $MRNA .

#美股 #MRNA #Biopharma

mrna

MRNA down nearly 17%; long liquidations outpace shorts by 4x

Trending Topics